Castro-Rodrigues, Pedro
Akam, Thomas http://orcid.org/0000-0002-1810-0494
Snorasson, Ivar http://orcid.org/0000-0002-5979-3151
Camacho, Marta
Paixão, Vitor http://orcid.org/0000-0003-3722-0747
Maia, Ana
Barahona-Corrêa, J. Bernardo http://orcid.org/0000-0001-8558-3126
Dayan, Peter http://orcid.org/0000-0003-3476-1839
Simpson, H. Blair
Costa, Rui M.
Oliveira-Maia, Albino J. http://orcid.org/0000-0001-5071-3007
Article History
Received: 11 September 2020
Revised: 19 March 2022
Accepted: 31 March 2022
First Online: 19 May 2022
Competing interests
: J.B.B.-C. received honoraria from Janssen-Cilag, Ltd, as a member of a local Advisory Board. H.B.S. has received research support for an industry-sponsored clinical trial from Biohaven Pharmaceuticals, royalties from UpToDate Inc. and a stipend from the American Medical Association for her role as Associate Editor of <i>JAMA Psychiatry</i>. A.J.O.-M. was the national coordinator for Portugal of a non-interventional study (EDMS-ERI-143085581, 4.0) to characterize a Treatment-Resistant Depression Cohort in Europe, sponsored by Janssen-Cilag, Ltd (2019–2020) and of a trial of psilocybin therapy for treatment-resistant depression, sponsored by Compass Pathways, Ltd (EudraCT nos. 2017-003288-36; 2020–2021); is recipient of a grant from Schuhfried GmBH for norming and validation of cognitive tests; and is national coordinator for Portugal of a trial of esketamine for treatment-resistant depression, sponsored by Janssen-Cilag, Ltd (EudraCT no. 2019-002992-33). The remaining authors declare no competing interests.